Skip to main content
. 2016 Nov 25;8(3):4875–4887. doi: 10.18632/oncotarget.13608

Figure 5. Immunofluorescent image demonstrating that nuclear translocation of AR in response to DHT or PMA can be inhibited by enzalutamide and BIM and nuclear translocation of AR578 in response to PMA can be inhibited by BIM.

Figure 5